Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Examining the Effect of Endogenous Glucagon-like Peptide-1 on Glucagon Secretion in Type 1 Diabetes
NCT07373236Completed
- Start
- Jan 2026
- Primary completion
- Apr 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Trial of exendin 9-39 in type 1 diabetes mellitus (T1D) (2 arms). Primary endpoint: Baseline-subtracted Area Under the Curve for Glucagon. Started Jan 2026; status: completed.
02
Drugs
exendin 9-39
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT07373236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07373236.